Johnson & Johnson (NYSE:JNJ) Q3 2020 Earnings Conference Call - Final Transcript
Oct 13, 2020 • 08:30 am ET
independent Data and Safety Monitoring Board or DSMB. DSMBs, as you know, are very commonly CAR-T [Phonetic] trials in the pharmaceutical industry. This Board is comprised of outside experts who evaluate the information and then, make a recommendation to us. In our case here, we were informed of unexpected illness on Sunday evening, October 11, and we followed our process exactly and quickly and posted a statement on our website the following day on Monday, October 12 pausing enrollment. The DSMB was inquired immediately on Sunday and they have requested additional information. We are now awaiting further medical information and evaluations, which we will then forward to the DSMB for their independent recommendation. We are absolutely committed to providing transparent updates throughout our vaccine development program, and we will update you when we learn more.
And finally, I would be remised that I didn't express great enthusiasm for the R&D portfolio at Janssen. I'm very excited about all the really tremendous progress we've made against the programs in our portfolio in spite of COVID-19, continue to make deep investments and terrific progress on currently marketed products to extend them further and against new molecular entities. Highlights were already mentioned that include DARZALEX FASPRO for AL amyloidosis progress as we continue to build on TREMFYA, amivantamab, our CD3 redirector franchise, BCMA CAR-T, RPGR gene therapy, and many others. So happy to address any of that in the Q&A.
I hand it now back to Chris DelOrefice. Chris?
Terrific. Thank you, Mathai, and thank you, Jennifer, Ashley and Thibaut. Rob, let's now move to questions from the investment community. Can you please provide instructions for those on the line wishing to ask a question?